{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:35:47Z","timestamp":1780511747528,"version":"3.54.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.disamonth.2024.101689","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:54:47Z","timestamp":1707245687000},"page":"101689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of gene therapy in sickle cell disease"],"prefix":"10.1016","volume":"70","author":[{"given":"Aishwarya","family":"Raghuraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudrakshi","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinela Vivas","family":"Pichardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amulya","family":"Mujakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4537","key":"10.1016\/j.disamonth.2024.101689_bib0001","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/178792a0","article-title":"A specific chemical difference between the globins of normal human and sickle-cell An\u00e6miaH\u00e6moglobin","volume":"178","author":"INGRAM","year":"1956","journal-title":"Nature"},{"issue":"7526","key":"10.1016\/j.disamonth.2024.101689_bib0002","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/515S10a","article-title":"Perspective: we need a global solution","volume":"515","author":"Odame","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101689_bib0003","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1517\/14712598.3.8.1215","article-title":"Haematopoietic cell transplantation in the treatment of sickle cell disease","volume":"3","author":"Atkins","year":"2003","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease","volume":"325","author":"Platt","year":"1991","journal-title":"New England J Med"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101689_bib0005","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101689_bib0006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101689_bib0007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101689_bib0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.disamonth.2024.101689_bib0009","unstructured":"WC M., S H., PR P., E H., E V. Availability of related donors for bone marrow transplantation in sickle cell anemia. PubMed.https:\/\/pubmed.ncbi.nlm.nih.gov\/8311169\/. Published 2022. Accessed September 11, 2022."},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0010","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.bbmt.2015.11.407","article-title":"Results of the blood and marrow transplant clinical trials network study BMT CTN 0601: scurt - a multicenter phase II trial of unrelated donor reduced intensity bone marrow transplantation (BMT) for children with severe sickle cell disease","volume":"22","author":"Shenoy","year":"2016","journal-title":"Biol Blood MarrowTranspl"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101689_bib0011","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"New England J Med"},{"key":"10.1016\/j.disamonth.2024.101689_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3949\/ccjm.87a.18051","article-title":"Sickle cell disease: a primary care update","volume":"87","author":"Onimoe","year":"2020","journal-title":"Cleve Clin J Med"},{"issue":"18 Suppl","key":"10.1016\/j.disamonth.2024.101689_bib0014","first-page":"S335","article-title":"Sickle cell disease: current treatment and emerging therapies","volume":"25","author":"Neumayr","year":"2019","journal-title":"Am J Manage Care"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101689_bib0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcyt.2018.04.003","article-title":"Gene therapy for sickle cell disease: an update","volume":"20","author":"Demirci","year":"2018","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101689_bib0016","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.17312","article-title":"Sickle cell disease: progress towards combination drug therapy","volume":"194","author":"Pace","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101689_bib0017","doi-asserted-by":"crossref","first-page":"e29075","DOI":"10.1002\/pbc.29075","article-title":"Sickle cell disease and COVID-19: susceptibility and severity","volume":"68","author":"Sayad","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101689_bib0018","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"key":"10.1016\/j.disamonth.2024.101689_bib0019","first-page":"2402","article-title":"Sickle cell disease","volume":"2016","author":"Meremikwu","year":"2016","journal-title":"BMJ Clin Evid"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hoc.2018.01.014","article-title":"Key components of pain management for children and adults with sickle cell disease","volume":"32","author":"Brandow","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101689_bib0021","first-page":"525","article-title":"Enfermedad de c\u00e9lulas falciformes: un diagn\u00f3stico para tener presente [Sickle cell disease: a diagnosis to keep in mind]","volume":"89","author":"Z\u00fa\u00f1iga","year":"2018","journal-title":"Rev Chil Pediatr"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101689_bib0022","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2013.09.001","article-title":"Management of sickle cell disease from childhood through adulthood","volume":"27","author":"Kanter","year":"2013","journal-title":"Blood Rev"},{"issue":"16","key":"10.1016\/j.disamonth.2024.101689_bib0023","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101689_bib0024","article-title":"Gene therapy for sickle cell disease","volume":"11","author":"Olowoyeye","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"6483","key":"10.1016\/j.disamonth.2024.101689_bib0025","first-page":"1198","article-title":"Treating sickle cell anemia","volume":"367","author":"Tisdale","year":"2020","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0026","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-022-01237-z","article-title":"Advances in the diagnosis and treatment of sickle cell disease","volume":"15","author":"Brandow","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0027","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.002","article-title":"New therapeutic options for the treatment of sickle cell disease","volume":"11","author":"Matte","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib86","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acs.bioconjchem.9b00130","article-title":"Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia","volume":"30","author":"Strader","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101689_bib0028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.31486\/toj.18.0076","article-title":"Sickle cell disease: advances in treatment","volume":"18","author":"Gardner","year":"2018","journal-title":"Ochsner J"},{"key":"10.1016\/j.disamonth.2024.101689_bib0029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fphys.2020.00435","article-title":"Recent advances in the treatment of sickle cell disease","volume":"11","author":"Salinas Cisneros","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.disamonth.2024.101689_bib0030","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.22433.1","article-title":"Drug therapies for the management of sickle cell disease","volume":"9","author":"Rai","year":"2020","journal-title":"F1000Res"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101689_bib0031","first-page":"895","article-title":"Sickle cell disease in children","volume":"72","author":"Meier","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.disamonth.2024.101689_bib0032","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101689_bib0033","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","article-title":"Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now","volume":"118","author":"Hsieh","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101689_bib0034","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41409-020-01054-3","article-title":"Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease","volume":"56","author":"Kharya","year":"2020","journal-title":"Bone Marrow TransPlant"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bjh.16437","article-title":"Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?","volume":"189","author":"Leonard","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0036","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing ofBCL11Ato treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"New England J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0037","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/hematology.2021000250","article-title":"Gene therapy for sickle cell disease: where we are now?","volume":"2021","author":"Kanter","year":"2021","journal-title":"Hematology"},{"issue":"7603","key":"10.1016\/j.disamonth.2024.101689_bib0063","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101689_bib0038","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/cells11111843","article-title":"Hematopoietic stem cell gene-addition\/editing therapy in sickle cell disease","volume":"11","author":"Germino-Watnick","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.disamonth.2024.101689_bib0039","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.disamonth.2024.101689_bib0040","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2024.101689_bib0041","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.disamonth.2024.101689_bib0042","doi-asserted-by":"crossref","first-page":"16059","DOI":"10.1038\/mtm.2016.59","article-title":"Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model","volume":"3","author":"Uchida","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0043","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pcl.2018.01.008","article-title":"Genetic therapies for sickle cell disease","volume":"65","author":"Jayavaradhan","year":"2018","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0044","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/hum.2015.110","article-title":"Insulated foamy viral vectors","volume":"27","author":"Browning","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/gt.2016.88","article-title":"Evidence for the in vivo safety of insulated foamy viral vectors","volume":"24","author":"Browning","year":"2017","journal-title":"Gene Ther"},{"issue":"Supplement 1","key":"10.1016\/j.disamonth.2024.101689_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140963","article-title":"Early results from a phase 1\/2 study of Aru-1801 gene therapy for sickle cell disease (SCD): manufacturing process enhancements improve efficacy of a modified gamma globin lentivirus vector and reduced intensity conditioning transplant","volume":"136","author":"Grimley","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.disamonth.2024.101689_bib0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136193","article-title":"Improvements in health-related quality of life for patients treated with lentiglobin for sickle cell disease (bb1111) gene therapy","volume":"136","author":"Kanter","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.disamonth.2024.101689_bib0047","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.3390\/ijms21186461","article-title":"Methods favoring homology-directed repair choice in response to crispr\/cas9 induced-double strand breaks","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2024.101689_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/bs.pmbts.2021.01.025","article-title":"Genome editing approaches to \u03b2-hemoglobinopathies","author":"Brusson","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101689_bib0049","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00439-016-1688-0","article-title":"Use of genome-editing tools to treat sickle cell disease","volume":"135","author":"Tasan","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.disamonth.2024.101689_bib0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101689_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"17","key":"10.1016\/j.disamonth.2024.101689_bib0056","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2017-10-811505","article-title":"Induction of fetal hemoglobin synthesis by CRISPR\/Cas9-mediated editing of the human \u03b2-globin locus","volume":"131","author":"Antoniani","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101689_bib0052","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.disamonth.2024.101689_bib0053","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","article-title":"Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin","volume":"33","author":"Bauer","year":"2015","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.disamonth.2024.101689_bib0054","first-page":"1839","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science (1979)"},{"key":"10.1016\/j.disamonth.2024.101689_bib0055","first-page":"993","article-title":"Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing","volume":"334","author":"Xu","year":"2011","journal-title":"Science (1979)"},{"key":"10.1016\/j.disamonth.2024.101689_bib0071","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.disamonth.2024.101689_bib0072","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9392","article-title":"Editing a \u03b3-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype","volume":"6","author":"Weber","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.disamonth.2024.101689_bib0073","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-142339","article-title":"Gene editing of KLF1 to cure sickle cell disease","volume":"136","author":"Gillinder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.disamonth.2024.101689_bib0074","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/bloodadvances.2019000820","article-title":"Genome editing of HBG1 and HBG2 to induce fetal hemoglobin","volume":"3","author":"M\u00e9tais","year":"2019","journal-title":"Blood Adv"},{"issue":"7577","key":"10.1016\/j.disamonth.2024.101689_bib0057","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"issue":"6155","key":"10.1016\/j.disamonth.2024.101689_bib0058","first-page":"253","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science (1979)"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101689_bib0067","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.disamonth.2024.101689_bib0069","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/mt.2016.148","article-title":"CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells","volume":"24","author":"Hoban","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.disamonth.2024.101689_bib0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.stem.2019.04.001","article-title":"highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination","volume":"24","author":"Martin","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.disamonth.2024.101689_bib0059","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41588-021-00904-0","article-title":"Activation of \u03b3-globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin","volume":"53","author":"Doerfler","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.disamonth.2024.101689_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e3283420fd0","article-title":"Update on fetal hemoglobin gene regulation in hemoglobinopathies","volume":"23","author":"Bauer","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.disamonth.2024.101689_bib0061","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65421","article-title":"Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin","volume":"11","author":"Ravi","year":"2022","journal-title":"Elife"},{"issue":"7785","key":"10.1016\/j.disamonth.2024.101689_bib0062","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"7681","key":"10.1016\/j.disamonth.2024.101689_bib0064","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022TtoG\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"issue":"7866","key":"10.1016\/j.disamonth.2024.101689_bib0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"issue":"Supplement_1","key":"10.1016\/j.disamonth.2024.101689_bib0068","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2019-127393","article-title":"Results from the completed Hgb-205 trial of lentiglobin for \u03b2-thalassemia and lentiglobin for sickle cell disease gene therapy","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101689_bib0066","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype","volume":"126","author":"Brendel","year":"2016","journal-title":"J Clinical Investig"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101689_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101689_bib0076","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14712598.2018.1536119","article-title":"Promise of gene therapy to treat sickle cell disease","volume":"18","author":"Romero","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.disamonth.2024.101689_bib0077","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.hoc.2009.11.002","article-title":"Hydroxyurea for children with sickle cell disease","volume":"24","author":"Heeney","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.disamonth.2024.101689_bib0078","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.disamonth.2024.101689_bib0079","unstructured":"Long-term follow-up of subjects with sickle cell disease treated with ex vivo gene therapy - full text view - clinicaltrials.gov. clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04628585. Published 2022. Accessed September 7, 2022."},{"issue":"Supplement 1","key":"10.1016\/j.disamonth.2024.101689_bib0081","first-page":"16","article-title":"Resolution of serious vaso-occlusive pain crises and reduction in patient-reported pain intensity: results from the ongoing phase 1\/2 HGB-206 group c study of lentiglobin for sickle cell disease (bb1111) gene therapy","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101689_bib0082","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.disamonth.2024.101689_bib0083","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/hum.2021.29159.bfs","article-title":"After analysis, bluebird bio says vector \u201cvery unlikely\u201d cause of acute myeloid leukemia","author":"Philippidis","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.disamonth.2024.101689_bib0084","doi-asserted-by":"crossref","unstructured":"Brunson, A.; Keegan, T.H.M.; Bang, H.; Mahajan, A.; Paulukonis, S.; Wun, T. Increased risk of leukemia among sickle cell disease patients in California. Blood 2017, 130, 1597\u20131599.","DOI":"10.1182\/blood-2017-05-783233"},{"key":"10.1016\/j.disamonth.2024.101689_bib0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T08:10:30Z","timestamp":1718871030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502924000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0011502924000154"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101689","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of gene therapy in sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101689"}}